Dec. 2 at 9:54 PM
$CORT 19 trading days to Relacorilant PDUFA date of 12/30/25, not counting X'mas day:
- Relacorilant is the first blockbuster drug from CORT;
- Relacorilant received Orphan Drug designation from both FDA and EMA;
- Multiple patents by composition of matter, method of use, and others with various expiration dates, e.g., one patent related to pharmaceutical formulations containing Relacorilant expires on 4/14/2040;
- The Orphan Drug designation can provide additional market exclusivity upon approval;
Revenue from Korlym was
$675M in 2024, and estimated at
$900M in 2025. The Relacorilant for Cushing should generate >
$1 billion in its first year, and should reach multiple billions per year in 5 years after launch.
Typical Price-to-Sales Ratios for pharmaceutical companies are around 5, therefore, conservatively,
S=
$1B => TP=
$50; (Korlym)
S=
$2B => TP=
$100; (K+Relacorilant)
S=
$3B => TP=
$150; (K+R+OvarianC)
S=
$4B => TP=
$200; (K+R+O)
S=
$5B => TP=
$250; (K+R+O+Dazucorilant)
S=
$6B => TP=
$300; (K+R+O+D)
